DH

David Haber

General Partner at Andreessen Horowitz

New York, New York

Invests in

  • Min Investment:

    $500,000.00
  • Max Investment:

    $40,000,000.00
  • Target Investment:

    $20,000,000.00

Skills

Venture Capital
Analytics
Start-ups
Entrepreneurship
LBO
Leadership
Portfolio Management
Private Equity
Financial Modeling
Economics
Deal Sourcing
Acquisitions
Management Consulting
Investments
Strategy
Equities
Asset Managment
Analysis
Data Analysis
Asset Management

Education

Work Experience

  • General Partner

    2021

2017 - 2020

  • VP, Firmwide Strategy & Corporate Development (Executive Office)

    2019 - 2020

    Working with our Chief Strategy Officer on Partnerships, New Ventures and M&A Working with our Co-CIOs and CTO on Firmwide Digital and Technology Strategy (with a focus on externalizing our infrastructure as a developer platform for our clients to build upon) Sourced strategic investments in Carta (Series D/E) & Ualá (Series B)

  • VP, Strategy & Corporate Development (Digital Finance)

    2017 - 2019

    Bond Street joined forces with Marcus to grow our Digital Finance business.

2013 - 2017

  • Founder, CEO

    2013 - 2017

    We're building a better future where access to financing for small business owners is simple, transparent and fair. Bond Street joined forces with Goldman Sachs in October 2017 to grow the firm's new Digital Finance business. www.bondstreet.com

2011 - 2013

  • Associate

    2011 - 2013

    Spark Capital is an early-stage venture capital firm with a focus on social, mobile, ecommerce, marketplace and infrastructure investments. Investments include: Twitter, Tumblr, Plaid, Oculus, Wayfair, Warby Parker, Admeld, Mark43, Orchard, 1stDibs, among others.

2008 - 2011

  • Founding Associate

    2008 - 2011

    Start-up asset management firm lead by Rory Riggs, a veteran private equity investor and biotech entrepreneur.

New Ventures

2008 - 2011

  • Associate

    2008 - 2011

    New Ventures is a $150M venture capital fund with investments in biotechnology and health care. (Portfolio includes: Royalty Pharma, Fibrogen, Cibus, GeneNews, DestinationRx, COH, etc.)